Bone Marrow (BM) Minimal Residual Disease (MRD) at End of Induction and Interim Maintenance Is Highly Predictive of Outcome in Children with Standard Risk (SR) Acute Lymphoblastic Leukemia (ALL) Treated on the Children’s Oncology Group Study 1991
Yousif Matloub(Roswell Park Comprehensive Cancer Center), Sharon R. Pine(University of Colorado Anschutz Medical Campus), Anne Angiolillo(Children's National), Paul S. Gaynon(University of Southern California), Naomi Winick(The University of Texas Southwestern Medical Center), William L. Carroll(NYU Langone Health), Meenakshi Devidas(National Institutes of Health), Stephen B. Linda(Children's Hospital of Wisconsin), Somasundaram Jayabose(New York Medical College), Bruce Bostrom(Minnesota West Community & Technical College), Harland N. Sather(Children's Oncology Group), Stephen P. Hunger(Children's Hospital of Philadelphia)
Cited by 1
Related Papers
Deletion of <i>IKZF1</i> and Prognosis in Acute Lymphoblastic Leukemia
|New England Journal of Medicine|2009|1.4k
Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia
|New England Journal of Medicine|2014|1.4k
Improved Survival for Children and Adolescents With Acute Lymphoblastic Leukemia Between 1990 and 2005: A Report From the Children's Oncology Group
|Journal of Clinical Oncology|2012|1.2k
Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration
|Journal of Clinical Oncology|2015|1k